Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia.
about
Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic ImplicationsDrug-induced dyskinesia in Parkinson's disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia?Metabotropic glutamate receptors: from the workbench to the bedside.Cellular and behavioral outcomes of dorsal striatonigral neuron ablation: new insights into striatal functions.Cell type-specific plasticity of striatal projection neurons in parkinsonism and L-DOPA-induced dyskinesia.Chemogenetic stimulation of striatal projection neurons modulates responses to Parkinson's disease therapy.L-DOPA neurotoxicity is mediated by up-regulation of DMT1-IRE expression.Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signalingInhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia.Priming for l-dopa-induced dyskinesia in Parkinson's disease: a feature inherent to the treatment or the disease?Maladaptive striatal plasticity in L-DOPA-induced dyskinesia.Role for the nicotinic cholinergic system in movement disorders; therapeutic implications.Dopamine transporter loss in 6-OHDA Parkinson's model is unmet by parallel reduction in dopamine uptake.Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats.Behavioral and cellular modulation of L-DOPA-induced dyskinesia by beta-adrenoceptor blockade in the 6-hydroxydopamine-lesioned rat.Glutamatergic pathways as a target for the treatment of dyskinesias in Parkinson's disease.Nicotinic receptor subtype-selective circuit patterns in the subthalamic nucleus.DARPP-32, Jack of All Trades… Master of Which?Neuregulin 1 signalling modulates mGluR1 function in mesencephalic dopaminergic neurons.L-Dihydroxyphenylalanine modulates the steady-state expression of mouse striatal tyrosine hydroxylase, aromatic L-amino acid decarboxylase, dopamine and its metabolites in an MPTP mouse model of Parkinson's diseaseA Genetic Mouse Model of Parkinson's Disease Shows Involuntary Movements and Increased Postsynaptic Sensitivity to Apomorphine.Zooming in on the small: the plasticity of striatal dendritic spines in L-DOPA-induced dyskinesia.Nicotine and Parkinson's disease: implications for therapy.Effect of adenosine A(2A) receptor antagonists and L-DOPA on hydroxyl radical, glutamate and dopamine in the striatum of 6-OHDA-treated ratsPharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist.Modulation of L-DOPA's antiparkinsonian and dyskinetic effects by α2-noradrenergic receptors within the locus coeruleusUnilateral Lesion of Dopamine Neurons Induces Grooming Asymmetry in the Mouse.Effects of the beta-adrenergic receptor antagonist Propranolol on dyskinesia and L-DOPA-induced striatal DA efflux in the hemi-parkinsonian ratEstablished patterns of animal study design undermine translation of disease-modifying therapies for Parkinson's diseaseα7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage.Nur77 mRNA levels and L-Dopa-induced dyskinesias in MPTP monkeys treated with docosahexaenoic acid.Effects of 5-HT1A receptor stimulation on D1 receptor agonist-induced striatonigral activity and dyskinesia in hemiparkinsonian rats.The effects of BMY-14802 against L-DOPA- and dopamine agonist-induced dyskinesia in the hemiparkinsonian ratOptogenetic activation of striatal cholinergic interneurons regulates L-dopa-induced dyskinesiasM4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced DyskinesiaNicotine-mediated improvement in L-dopa-induced dyskinesias in MPTP-lesioned monkeys is dependent on dopamine nerve terminal functionExogenous corticosterone reduces L-DOPA-induced dyskinesia in the hemi-parkinsonian rat: role for interleukin-1beta.Striatal 5-HT1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat.Levodopa-induced dyskinesia and striatal signaling pathwaysNeurochemical changes in the striatum of dyskinetic rats after administration of the cannabinoid agonist WIN55,212-2
P2860
Q21129423-12693686-CDF3-4891-955E-6CA46C6EE85AQ27021464-9A6374D8-53FE-40FA-B9B4-FE568ECD6A4EQ30448778-7C30553A-2533-4408-AC89-930B9AD523FCQ30595759-EE6D7ED7-C3FE-4339-9DB7-8FF38E6B9370Q30650489-C63ABDA3-58BA-49DA-81BB-5E83841E503AQ30836713-FC598006-C9A8-4DE7-A190-40F5FC289C85Q33412141-5C59FB5D-0FE6-4ED6-AB97-B47935F06E47Q33428476-55D6A43B-894B-44AB-8650-EE188D34D487Q33758221-ECC5C457-AA45-448A-87E0-7292934C5FF4Q34044620-BA80B4C1-C937-4618-A464-26D2A0FC1018Q34094008-02A04AE9-5009-4DCE-BCE6-92F8DA1249B1Q34112026-7EE05EA0-3D40-4BF7-A659-E29731D1708DQ34540567-BC94F0E1-757C-4069-A6C7-85644DD90F61Q35000569-F5B50C3D-AE7E-4392-B87D-4BCC66FE6DB4Q35003086-E17E2229-D05E-4ED4-BF60-1CF3FFE9E509Q35124773-150CF002-7E25-4018-890E-69E1B249199CQ35142884-B1A4CBB0-C578-4129-A30F-160EFA89BF82Q35201971-0E436169-6FA2-4D2E-A996-F00BC02B6D6CQ35285315-2050C1C0-C60B-4343-BA8D-FC3864C00A4DQ35291721-EC7B4935-E84C-4FF9-B014-61B05C02F95CQ35324207-398A6126-F753-4E16-ABF0-33514973E382Q35574934-0EACD0EF-A412-481F-9221-F4E3A6B38851Q35601652-C147ACBB-BA7C-4418-A96B-3A7578649059Q35635814-20E60047-8ABB-4FF5-A421-A27037D69C7DQ35738538-41CF23B0-3442-4463-8167-F12C7416FBBCQ35738678-C06277CA-F073-489A-ACBF-77F1D23264E1Q35784656-DF43EC5D-5D9B-4004-98B8-D7284C5EA5FEQ35815701-00B8E7F7-46B6-4F04-94E0-B8AC5B735362Q36275707-9760FE55-4C4A-495D-B99B-562E03278228Q36469995-8ED0BBF1-C59C-47A4-9241-32C9FEBBAC3BQ36727014-BFBDAA4D-1180-484F-B1C1-EDA08019E444Q36851672-6BA97FE0-0661-47FE-82BC-3A2EC308B63CQ36852272-9BC49962-4E37-4B72-B757-C0CECF9AEA8EQ36880148-74162E09-AF23-4609-9F90-44EAD3AFDE10Q36892615-56B1685C-60D4-438A-9E8A-C69895DC6318Q36936920-D655CA7C-B938-418F-ABB3-EC09A2DE5029Q37040535-DB6E45AB-D1BE-49C0-8609-B4FCA3132C78Q37103028-48942AC6-9BC2-4E30-891C-8101F73050AEQ37117536-72680A7E-71C4-472C-9814-D05CC13247DFQ37132571-BE2B4E08-474A-4F57-87DA-E5C667A2AE43
P2860
Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia.
description
2007 nî lūn-bûn
@nan
2007 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
name
Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia.
@ast
Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia.
@en
Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia.
@nl
type
label
Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia.
@ast
Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia.
@en
Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia.
@nl
prefLabel
Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia.
@ast
Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia.
@en
Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia.
@nl
P1476
Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia.
@en
P2093
M Angela Cenci
P304
P356
10.1016/J.TINS.2007.03.005
P577
2007-04-02T00:00:00Z